Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Song GY, Kim HJ, Kim T, Ahn SY, Jung SH, Kim M, Yang DH, Lee JJ, Kim MY, Cheong JW, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Park SK, Kim SH, Choi CK, Kim HJ, Ahn JS, Kim DDH. Song GY, et al. Among authors: jung cw. Sci Rep. 2024 Apr 12;14(1):8517. doi: 10.1038/s41598-024-57295-5. Sci Rep. 2024. PMID: 38609396 Free PMC article.
Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype.
Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Lee JY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Lee YJ, Won JH, Kim SH, Zhang Z, Kim T, Kim DDH. Ahn JS, et al. Among authors: jung cw, jung sh. Oncotarget. 2017 Dec 22;9(4):4961-4968. doi: 10.18632/oncotarget.23575. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435155 Free PMC article.
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.
Song GY, Kim T, Ahn SY, Jung SH, Kim M, Yang DH, Lee JJ, Choi SH, Kim MY, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Park SK, Kim SH, Zhang Z, Ahn JS, Kim HJ, Kim DDH. Song GY, et al. Among authors: jung cw, jung sh. Bone Marrow Transplant. 2022 Dec;57(12):1810-1819. doi: 10.1038/s41409-022-01817-0. Epub 2022 Sep 23. Bone Marrow Transplant. 2022. PMID: 36151367
Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
Ahn SY, Kim T, Kim M, Song GY, Jung SH, Yang DH, Lee JJ, Kim MY, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim HJ, Ahn JS, Kim DDH. Ahn SY, et al. Among authors: jung cw, jung sh. Cancer Res Treat. 2023 Jul;55(3):1011-1022. doi: 10.4143/crt.2022.1407. Epub 2023 Jan 26. Cancer Res Treat. 2023. PMID: 36701843 Free PMC article.
Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.
Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Lee IK, Kim NY, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim N, Yoshida K, Ogawa S, Kim DD. Ahn JS, et al. Among authors: jung cw, jung sh. Haematologica. 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227. Epub 2015 Jun 4. Haematologica. 2015. PMID: 26045292 Free PMC article. No abstract available.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: jung cw, jung sh. Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31. Biol Blood Marrow Transplant. 2016. PMID: 26234722 Free article. Clinical Trial.
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: jung cw, jung sh. Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Ann Hematol. 2016. PMID: 26537612
Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: jung cw, jung sh. Ann Hematol. 2016 Jan;95(2):363. doi: 10.1007/s00277-015-2563-0. Ann Hematol. 2016. PMID: 26630982 No abstract available.
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: jung cw, jung sh. Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22. Ann Hematol. 2016. PMID: 26692090
477 results